Boehringer Ingelheim expands cancer research at its Vienna site
- Inauguration of Angelika Amon research building in Vienna
- Sustainable research building at a cost of EUR 60 million offers modern office and laboratory space
- Over the past five years, Boehringer’s capital investments reached EUR 6.0 billion
Boehringer Ingelheim is one of the world's leading research-oriented pharmaceutical companies. The clinical pipeline is constantly being further developed, and Boehringer Ingelheim expects new approvals also in oncology in the coming years.
An important investment in the future is the new Angelika Amon Research Building, opened on September 25, in the presence of guests from politics and science. The modern and sustainable building offers ideal conditions for researchers on 11 floors, where 150 people work on promising therapeutic approaches against cancer in an environment fitted with the state-of-the-art research equipment. It is named after the internationally renowned Viennese cancer researcher Angelika Amon (1967–2020) who was closely connected to Boehringer Ingelheim. The investment sum of around EUR 60 million is another testimony to Boehringer Ingelheim's commitment to cancer research.
However, the completion of the new research building is only one of many investments. To support the company’s growth, Boehringer announced last year a 5-year plan, covering EUR 7.0 billion capital investment. In 2023, capital expenditure reached EUR 1.2 billion under this program. Over the past five years, Boehringer’s capital investments amounted to EUR 6.0 billion.
Hope in the fight against cancer
R&D investments in Human Pharma rose to EUR 5.8 billion in 2023, around 25% of Human Pharma net sales, ranking Boehringer Ingelheim among the top R&D investors in the industry. "Our goal is to create more health for humans and animals," says Paola Casarosa, Head of Innovation Unit, explaining the focus on a promising and broad portfolio in the fight against cancer. "Especially in the field of oncology, there is still a massive unmet medical need. We are working with great enthusiasm to make cancer a treatable disease."
Norbert Kraut, Global Head of Cancer Research, says "Our declared goal is to cure cancer. The big challenge is that cancer is not a single disease, but a term for different diseases of different organs. In the future, around one third of the new products at Boehringer Ingelheim will come from oncology."
New high-tech facility
Newest technologies and laboratories allow scientists to faster achieve their goal to develop innovative therapies for people living with cancer. The new building with a gross floor space of circa 11,000 sqm is also state-of-the-art in terms of sustainability. Photovoltaic arrays on the roof and the façade of the 38 m high building save 45 tons of CO2 per year. Electrochromic glass darkens automatically with the sunlight and reduces cooling requirements by 30%.
Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at https://www.boehringer-ingelheim.com.
Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
- 日本酒造组合中央会将于7月在福冈举办活动,届时您可以享用本格烧酒、泡盛和美食!!
- Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Sh
- 哈工小愈(北京)与哈工天愈招商会在鸟巢成功举办
- 国际贸易供应链:全球贸易的纽带与引擎
- “护苗”在行动 安全伴成长
- Parse Biosciences推出Trailmaker数据分析平台以简化单细胞测序
- 大变革时代,这家央企的反应堪称经典
- 青岛啤酒闪耀“新生万物”巴黎展,携手中华美食共襄“中法文化之光”
- FLOWER NINE2024 长城大秀·新品长城首发圆满成功
- 提升车险客户保险保障,履行央企行业担当
- 与安全“童”行 肯德基守护未来之星
- 铭泰慧谷(三河)孵化器有限公司成功签署科创园区合作框架协议
- 腾盾双尾蝎无人机连夜驰援四川雅江森林火灾扑救工作
- L6599AN: Revolutionizing Power Factor Correction in High-Efficiency Converters | ChipsX
- 健康保养产业.手机 助您重拾身体平衡与健康
- 借助禾蛙之力,外包供应商成功拓展猎头业务并每月轻松产出Offer20w+
- 国货品牌之光,不忘初心,于楠,凯萨蒂持续深耕品牌实力!
- 春防磨利刃 救援当尖刀丨阿勒泰森林消防多措并举全面做好春防战备工作
- EFG与Qiddiya新城达成五年合作 携手推进电竞产业发展
- Cirium的Emerald Sky将带来飞机排放和燃油消耗数据准确性的变革
- 全适乐蕊,用双盲临床验证效果,用亲民价格守护孩子睛彩未来
- 引领MZ潮流风向 新潮美食狙击味蕾
- Newmont任命采矿业资深人士Francois Hardy为首席技术官
- 2月27日,华奇资本与德太资本举行签约仪式,拉开合作序幕!
- Duck Creek Technologies Recognizes IAT Insurance Group and Coforge with its Standard of Excellence A
- BASF Environmental Catalyst and Metal Solutions (ECMS) completes acquisition of Arc Metal AB in Swed
- FastMoss大升级!数据库扩充30%,商品达人分析新增多个维度,会员权益加量不加价
- 飞驰环球欧陆景行庆祝中俄文化年书画名家联展走进莫斯科
- 阳光人寿上海分公司举办“巾帼绽芳华”插花活动 迎接“三八”国际妇女节
- 赏析《酒文化小品集》:秦含章,当代诗酒文化第一人
推荐
- 男子“机闹”后航班取消,同机旅客准备集体起诉 1月4日,一男子大闹飞机致航班取消的新闻登上 资讯
- 中国减排方案比西方更有优势 如今,人为造成的全球变暖是每个人都关注的问 资讯
- 大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯
- 新增供热能力3200万平方米 新疆最大热电联产项目开工 昨天(26日),新疆最大的热电联产项目—&md 资讯
- 抖音直播“新红人”进攻本地生活领域 不难看出,抖音本地生活正借由直播向本地生活 资讯
- 周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加 周星驰新片《少林女足》在台湾省举办海选,吸 资讯
- 看新东方创始人俞敏洪如何回应董宇辉新号分流的? (来源:中国证券报) 东方甄选净利润大幅下滑 资讯
- 海南大学生返校机票贵 有什么好的解决办法吗? 近日,有网友在“人民网领导留言板&rdqu 资讯
- 透过数据看城乡居民医保“含金量” 缴费标准是否合理? 记者从国家医保局了解到,近期,全国大部分地区 资讯
- 产业数字化 为何需要一朵实体云? 改革开放前,国内供应链主要依靠指标拉动,其逻 资讯